BTG3 and systemic lupus erythematosus: Clinically unaffected relatives (1-37%) in the LFRR had similar rates of immunologic criteria and immune modulating treatments as matched HC (1-30%), but were once again more likely than HC to be ANA positive (43% Rel vs. 21% HC, p<0.0001, Table 5), reinforcing an important difference between lupus relatives who remain clinically unaffected and demographically matched healthy individuals in the general population.